AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03724838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Patients will take Sildenafil Citrate 40mg every 8 hours
Study NCT03724838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Esomeprazole
Description: Patients will take inert tablets similar in appearance, color, and consistency to esomeprazole single dose of 40 mg orally once a day
Study NCT02347319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pennel
Description: Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
Study NCT02347319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Legalon
Description: Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
Study NCT02347319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
Study NCT02001051 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adrenalectomy
Description: Surgery to remove tumor when enrolled in the protocol.
Study NCT02001051 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Observation for 6 months prior to surgery
Study NCT00062101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally (PO)
Study NCT00062101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given PO
Study NCT03724838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Sildenafil Citrate
Description: Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
Study NCT00062101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01221831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estetrol, P 1 and placebo tablets
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P1 tablet per day~* Days 25-28: two placebo tablets per day
Study NCT01221831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estetrol, P2 and placebo tablets
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P2 tablet per day~* Days 25-28: two placebo tablets per day
Study NCT01221831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol valerate, dienogest and placebo tablets
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-26: one tablet of Estradiol valerate/dienogest per day~* Days 26-28: one placebo tablet per day
Study NCT02918682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - FIRST PHASE
Description: the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;
Study NCT02918682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - SECOND PHASE
Description: the participants do not need to perform the second phase or can advance to the third phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8-1 m/s and ability to walk 60 meters; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO and FFEC stance for more than 5 seconds and the Tandem EO stance for 10-20 seconds; 4. Having sitting stability limits with eyes closed; 5. Being able to bend the trunk forward, standing parallel to a wall, between 20-32 cm ad being stable. For muscle strength: being able to perform hip flexion with 60% of 1 RM for 8 repetitions; hip extension with 60% of 1RM for 8 repetitions; hip abduction without load but between 8-12 repetitions; knee extension with 60% of 1RM for 8 repetitions; knee flexion with 60% of 1RM for 8 repetitions;
Study NCT02918682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - FOURTH PHASE
Description: at the end of the exercise protocol, the participants who have reached the fourth phase must be able to achieve: 1. Gait speed of 0.8-1 m/s and able to walk 90 meters; 2. Stand up and sit down five times from the chair properly within less than 15 seconds; 3. TUG performance less than 14 seconds; 4. Maintenance of 30 seconds in FFEO and FFEC stance, maintenance of 30 seconds in Tandem EO and Tandem EC stance, maintenance of the single-leg stance for more than 21 seconds; 5. Normal sitting stability limits with eyes closed; 6. Bending the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For muscle strength: able to perform hip flexion with 70% of 1 RM for 6-10 repetitions; hip extension with 70% of 1RM for 6-10 repetitions; hip abduction with 40-60% of 1RM for 8-12 repetitions; knee extension with 70% of 1RM for 6-10 repetitions; knee flexion with 70% of 1RM for 6-10 repetitions.
Study NCT02918682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - THIRD PHASE
Description: participants do not need to perform the third phase or can advance to the fourth phase if they have obtained: 1 Gait speed of 0.8-1 m/s and walk 90 meters; 2 perform the stand up and sit down five times from the chair properly within less than 15 seconds; 3 Performing the TUG test within less than 14 seconds; 4 Maintaining the FFEO and FFEC stance for 30 seconds, maintaining the Tandem EO and Tandem EC stance for 30 seconds and maintaining the single-leg stance for more than 20 seconds; 5 Having sitting stability limits with eyes closed; 6 In the upright position, to bend the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For the muscle strength test, perform hip flexion with 60 % of 1 RM for 8-12 repetitions; hip extension with 60 % of 1RM for 8-12 repetitions; hip abduction without load or 5% of 1RM for hip abductor and between 8-12 repetitions; knee extension with 60 % of 1RM for 8-12 repetitions; knee flexion with 60 % of 1RM for 8-12 repetitions;
Study NCT03724838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Sildenafil Citrate
Description: Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
Study NCT05886231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music sound therapy
Description: investigate the effects of music on intraoperative hemodynamic parameters, anesthesia depth, muscle relaxant consumption, analgesic consumption and pain and side effects (nausea, vomiting, tremor) in the early postoperative period in patients undergoing thyroidectomy operation under general anesthesia.
Study NCT00937846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1034702
Description: Single oral 5 mg dose in liquid formulation
Study NCT02114749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a set of wearable respiration and cardiac monitoring devices
Description: feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
Study NCT02999048 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Panax Notoginseng Saponins
Description: Panax Notoginseng Saponins integrated with conventional therapy
Study NCT01844141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 70% alcohol
Description: After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
Study NCT03241316 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observational study of behaviour
Description: As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
Study NCT01754987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid + Sorafenib
Study NCT01754987 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Study NCT04235257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose
Study NCT04474431 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
Description: Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
Study NCT02033135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty with Zilver PTX
Description: Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
Study NCT02033135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
Study NCT02033135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
Study NCT01844141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70% alcohol - 0.5% clorhexidine
Description: In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
Study NCT02139449 — intervention group
Intervention type: PROCEDURE
Intervention: ICD/CRT
Description: cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
Study NCT02033135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver PTX
Study NCT03710317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbetocin
Description: 100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
Study NCT02435199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401 600mg
Study NCT02435199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02777099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic postconditioning
Description: Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.
Study NCT02777099 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham remote ischemic postconditioning
Description: Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.
Study NCT00744393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium oxybate
Description: The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
Study NCT00744393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
Study NCT02205762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Stratum I
Study NCT02205762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Stratum I
Study NCT02537106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1.5% NaCl
Description: After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
Study NCT02537106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3% NaCl
Description: After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
Study NCT02205762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Stratum I
Study NCT02205762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDOMETHACIN
Description: Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
Study NCT02205762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: fixed dose weekly orally for total treatment duration of 24 months.
Study NCT02205762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosine Arabinoside
Study NCT02205762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine
Study NCT02205762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell transplantation (RIC-HSCT)
Study NCT02205762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Study NCT02246816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Description: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Study NCT02655367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flaked oats
Description: Test meal consisting of 264g porridge made with flaked oats
Study NCT02655367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milled oats
Description: Test meal consisting of 264g porridge made with milled oats
Study NCT02865733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remodulin
Description: After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
Study NCT02865733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
Study NCT01852019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8
Study NCT01852019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8.
Study NCT02196818 — intervention group
Intervention type: DEVICE
Intervention: Mpact Acetabular Shell
Description: Total Hip Replacement
Study NCT05147389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AI model classification
Description: AIWorks is an artificial intelligence model for real-time cholangioscopic detection of neoplastic and non-neoplastic bile duct lesions. It allows you to choose using a video file or a USB camera input as the detection source. Once the input source has been selected, the software performs real-time detection by surrounding the area of interest (i.e., the area with malignancy features) inside a bounding box. All detections made are displayed on the right side of the screen and can also be reviewed afterwards.
Study NCT05147389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DSOC endoscopist experts' classification
Description: Six endoscopists with high DSOC expertise will observe and classify a set of videos among neoplastic or non-neoplastic bile duct lesions following a Bernoulli distribution; blinded to clinical records and should have never attended said patients.~Gastroenterologists from each center, with non-DSOC responsibility, will select DSOC videos and corresponding baseline data. DSOC videos and data will be gathered in one set. Each video represents a full DSOC for a single patient. The patient will be the unit of this study.~The neoplastic bile duct criteria are in accordance with the Robles-Medranda et al and the Mendoza classifications (ie. Irregular mucosa surface, Tortuous and dilated vascularity, Irregular nodulations, Polyps, Ulceration, Honeycomb pattern, etc.). The experts will assess neoplastic bile duct by presence or absence of disaggregated criteria. Likewise, by Boolean logical operators, the statistical software will compute disaggregated answers.
Study NCT04314830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training with perturbations
Description: Changes in speed of one of the belt of the split belt treadmill during swing phase
Study NCT04314830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait training without perturbation
Description: Walking on a treadmill with steady belt speed
Study NCT04980261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF + autograft
Description: Patients will undergo a standard open reduction internal fixation (ORIF) procedure with autograft implantation (from the iliac crest).
Study NCT00372190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tensionfree vaginal mesh kit (Prolift)
Description: Insertion of a tension free vaginal mesh using a Prolift mesh kit
Study NCT00372190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic vaginal prolapse surgery (fascia plication)
Description: classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
Study NCT02347111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: flecainide up to 150mg twice daily for the control of atrial fibrillation
Study NCT02347111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotalol
Description: sotalol up to 120mg twice daily for the control of atrial fibrillation
Study NCT03297099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted Laparoscopic operation
Description: Thirty patients with hepatolithiasis were selected and divided into robot group as described in the detailed description. Under general anesthesia, the patient was placed in a supine 30-degree reverse Trendelengburg position with both legs separating. The surgeon work on the console, and assist surgeon stand between legs. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
Study NCT03297099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: surgery group as described in the detailed description.Open surgery was performed under general anesthesia with the patient in the supine position. Routinely, a reversed L-shape incision was performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
Study NCT00162305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-512148
Description: Capsules, Oral, 100 mg, Once daily, 14 days.
Study NCT00162305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-512148
Description: Capsules, Oral, 25 mg, Once daily, 14 days.
Study NCT00162305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-512148
Description: Capsules, Oral, 5 mg, Once daily, 14 days.
Study NCT00162305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, Once daily, 14 days.
Study NCT01341431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bee venom
Description: 12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
Study NCT01341431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bee venom
Description: 12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.